{"title":"基于大鼠生物分布数据的188re - hynici - bombesin人体吸收剂量估算。","authors":"Sara Vosoughi, Nafise Salek, Hassan Yousefnia, Milad Delavari, Seyed Mahmoud Reza Aghamiri, Hassan Ranjbar","doi":"10.2174/1874471015666220919124037","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>HYNIC-Bombesin (BBN) is a potential peptide for targeted radionuclide therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies. The <sup>188</sup>Re-HYNICBBN is a promising radiopharmaceutical for use in prostate cancer therapy.</p><p><strong>Objective: </strong>The aim of this study was to estimate the absorbed dose due to <sup>188</sup>Re-HYNIC-BBN radio-complex in human organs based on bio-distribution data of rats.</p><p><strong>Methods: </strong>In this research, using bio-distribution data of <sup>188</sup>Re-HYNIC-BBN in rats, its radiation absorbed dose of the adult human was calculated for different organs based on the MIRD dose calculation method.</p><p><strong>Results: </strong>A considerable equivalent dose amount of <sup>188</sup>Re-Hynic-BBN (0.093 mGy/MBq) was accumulated in the prostate. Moreover, all other tissues except for the kidneys and pancreas approximately received insignificant absorbed doses.</p><p><strong>Conclusion: </strong>Since the acceptable absorbed dose for the complex was observed in the prostate, <sup>188</sup>Re-Hynic-Bombesin can be regarded as a new potential agent for prostate cancer therapy.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 1","pages":"64-70"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Estimation of Human Absorbed Dose of <sup>188</sup>Re-Hynic-Bombesin Based on Biodistribution Data in Rats.\",\"authors\":\"Sara Vosoughi, Nafise Salek, Hassan Yousefnia, Milad Delavari, Seyed Mahmoud Reza Aghamiri, Hassan Ranjbar\",\"doi\":\"10.2174/1874471015666220919124037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>HYNIC-Bombesin (BBN) is a potential peptide for targeted radionuclide therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies. The <sup>188</sup>Re-HYNICBBN is a promising radiopharmaceutical for use in prostate cancer therapy.</p><p><strong>Objective: </strong>The aim of this study was to estimate the absorbed dose due to <sup>188</sup>Re-HYNIC-BBN radio-complex in human organs based on bio-distribution data of rats.</p><p><strong>Methods: </strong>In this research, using bio-distribution data of <sup>188</sup>Re-HYNIC-BBN in rats, its radiation absorbed dose of the adult human was calculated for different organs based on the MIRD dose calculation method.</p><p><strong>Results: </strong>A considerable equivalent dose amount of <sup>188</sup>Re-Hynic-BBN (0.093 mGy/MBq) was accumulated in the prostate. Moreover, all other tissues except for the kidneys and pancreas approximately received insignificant absorbed doses.</p><p><strong>Conclusion: </strong>Since the acceptable absorbed dose for the complex was observed in the prostate, <sup>188</sup>Re-Hynic-Bombesin can be regarded as a new potential agent for prostate cancer therapy.</p>\",\"PeriodicalId\":10991,\"journal\":{\"name\":\"Current radiopharmaceuticals\",\"volume\":\"16 1\",\"pages\":\"64-70\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1874471015666220919124037\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1874471015666220919124037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Estimation of Human Absorbed Dose of 188Re-Hynic-Bombesin Based on Biodistribution Data in Rats.
Background: HYNIC-Bombesin (BBN) is a potential peptide for targeted radionuclide therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies. The 188Re-HYNICBBN is a promising radiopharmaceutical for use in prostate cancer therapy.
Objective: The aim of this study was to estimate the absorbed dose due to 188Re-HYNIC-BBN radio-complex in human organs based on bio-distribution data of rats.
Methods: In this research, using bio-distribution data of 188Re-HYNIC-BBN in rats, its radiation absorbed dose of the adult human was calculated for different organs based on the MIRD dose calculation method.
Results: A considerable equivalent dose amount of 188Re-Hynic-BBN (0.093 mGy/MBq) was accumulated in the prostate. Moreover, all other tissues except for the kidneys and pancreas approximately received insignificant absorbed doses.
Conclusion: Since the acceptable absorbed dose for the complex was observed in the prostate, 188Re-Hynic-Bombesin can be regarded as a new potential agent for prostate cancer therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
